Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Geddes
Rob Butler

Showing results (131-140 of 146) with videos related to

Pageof 15
Sort By:
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 4, 2026
Recommendations of the ECNP Digital Network for the evaluation of mental health care apps: A Delphi consensusBlanca Bolea, Diego Hidalgo-Mazzei, John Geddes, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Evidence-Based Mental Health|November 23, 2021
PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depressionSheena Kristine Au-Yeung, James Griffiths, Sophie Roberts, et al.
Contemporary Clinical Trials Communications|April 16, 2025
Reducing inequalities through greater diversity in clinical trials - As important for medical devices as for drugs and therapeuticsLaurence S J Roope, Jessica Walsh, Maddie Welland, et al.
Studies in Health Technology and Informatics|July 11, 2006
Designing for e-Health: recurring scenarios in developing grid-based medical imaging systemsJohn Geddes, Clare Mackay, Sharon Lloyd, et al.
Brain : a Journal of Neurology|June 9, 2022
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitisAdam Al-Diwani, Jakob Theorell, Valentina Damato, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 14, 2008
Wake-up call for British psychiatryNick Craddock, Danny Antebi, Mary-Jane Attenburrow, et al.
Health Technology Assessment (Winchester, England)|June 2, 2025
Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trialHamish McAllister-Williams, Nicola Goudie, Lumbini Azim, et al.
Journal of Psychopharmacology (Oxford, England)|January 20, 2025
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)R Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, et al.
Pageof 15

Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Trials|August 1, 2021
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept studyArjune Sen, Mary Akinola, Xin You Tai, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 4, 2026
Recommendations of the ECNP Digital Network for the evaluation of mental health care apps: A Delphi consensusBlanca Bolea, Diego Hidalgo-Mazzei, John Geddes, et al.
Epilepsia Open|October 14, 2024
Safety, tolerability, and efficacy outcomes of the Investigation of Levetiracetam in Alzheimer's disease (ILiAD) study: a pilot, double-blind placebo-controlled crossover trialArjune Sen, Sofia Toniolo, Xin You Tai, et al.
Evidence-Based Mental Health|November 23, 2021
PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depressionSheena Kristine Au-Yeung, James Griffiths, Sophie Roberts, et al.
Contemporary Clinical Trials Communications|April 16, 2025
Reducing inequalities through greater diversity in clinical trials - As important for medical devices as for drugs and therapeuticsLaurence S J Roope, Jessica Walsh, Maddie Welland, et al.
Studies in Health Technology and Informatics|July 11, 2006
Designing for e-Health: recurring scenarios in developing grid-based medical imaging systemsJohn Geddes, Clare Mackay, Sharon Lloyd, et al.
Brain : a Journal of Neurology|June 9, 2022
Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitisAdam Al-Diwani, Jakob Theorell, Valentina Damato, et al.
The British Journal of Psychiatry : the Journal of Mental Science|August 14, 2008
Wake-up call for British psychiatryNick Craddock, Danny Antebi, Mary-Jane Attenburrow, et al.
Health Technology Assessment (Winchester, England)|June 2, 2025
Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trialHamish McAllister-Williams, Nicola Goudie, Lumbini Azim, et al.
Journal of Psychopharmacology (Oxford, England)|January 20, 2025
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)R Hamish McAllister-Williams, Nicola Goudie, Lumbini Azim, et al.
Pageof 15